7d9r: Difference between revisions
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
The entry | ==Structure of huamn soluble guanylate cyclase in the riociguat and NO-bound state== | ||
<StructureSection load='7d9r' size='340' side='right'caption='[[7d9r]], [[Resolution|resolution]] 3.70Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[7d9r]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7D9R OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7D9R FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 3.7Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=G2P:PHOSPHOMETHYLPHOSPHONIC+ACID+GUANYLATE+ESTER'>G2P</scene>, <scene name='pdbligand=GZO:methyl+~{N}-[4,6-bis(azanyl)-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]-~{N}-methyl-carbamate'>GZO</scene>, <scene name='pdbligand=HEM:PROTOPORPHYRIN+IX+CONTAINING+FE'>HEM</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7d9r FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7d9r OCA], [https://pdbe.org/7d9r PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7d9r RCSB], [https://www.ebi.ac.uk/pdbsum/7d9r PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7d9r ProSAT]</span></td></tr> | |||
</table> | |||
== Disease == | |||
[https://www.uniprot.org/uniprot/GCYA1_HUMAN GCYA1_HUMAN] Moyamoya disease with early-onset achalasia. The disease is caused by mutations affecting the gene represented in this entry. | |||
== Function == | |||
[https://www.uniprot.org/uniprot/GCYA1_HUMAN GCYA1_HUMAN] | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Soluble guanylate cyclase (sGC) is the receptor for nitric oxide (NO) in human. It is an important validated drug target for cardiovascular diseases. sGC can be pharmacologically activated by stimulators and activators. However, the detailed structural mechanisms, through which sGC is recognized and positively modulated by these drugs at high spacial resolution, are poorly understood. Here, we present cryo-electron microscopy structures of human sGC in complex with NO and sGC stimulators, YC-1 and riociguat, and also in complex with the activator cinaciguat. These structures uncover the molecular details of how stimulators interact with residues from both beta H-NOX and CC domains, to stabilize sGC in the extended active conformation. In contrast, cinaciguat occupies the haem pocket in the beta H-NOX domain and sGC shows both inactive and active conformations. These structures suggest a converged mechanism of sGC activation by pharmacological compounds. | |||
Activation mechanism of human soluble guanylate cyclase by stimulators and activators.,Liu R, Kang Y, Chen L Nat Commun. 2021 Sep 17;12(1):5492. doi: 10.1038/s41467-021-25617-0. PMID:34535643<ref>PMID:34535643</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 7d9r" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Guanylate cyclase 3D structures|Guanylate cyclase 3D structures]] | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | |||
[[Category: Chen L]] | |||
[[Category: Kang Y]] | |||
[[Category: Liu R]] | |||
Latest revision as of 22:31, 29 May 2024
Structure of huamn soluble guanylate cyclase in the riociguat and NO-bound stateStructure of huamn soluble guanylate cyclase in the riociguat and NO-bound state
Structural highlights
DiseaseGCYA1_HUMAN Moyamoya disease with early-onset achalasia. The disease is caused by mutations affecting the gene represented in this entry. FunctionPublication Abstract from PubMedSoluble guanylate cyclase (sGC) is the receptor for nitric oxide (NO) in human. It is an important validated drug target for cardiovascular diseases. sGC can be pharmacologically activated by stimulators and activators. However, the detailed structural mechanisms, through which sGC is recognized and positively modulated by these drugs at high spacial resolution, are poorly understood. Here, we present cryo-electron microscopy structures of human sGC in complex with NO and sGC stimulators, YC-1 and riociguat, and also in complex with the activator cinaciguat. These structures uncover the molecular details of how stimulators interact with residues from both beta H-NOX and CC domains, to stabilize sGC in the extended active conformation. In contrast, cinaciguat occupies the haem pocket in the beta H-NOX domain and sGC shows both inactive and active conformations. These structures suggest a converged mechanism of sGC activation by pharmacological compounds. Activation mechanism of human soluble guanylate cyclase by stimulators and activators.,Liu R, Kang Y, Chen L Nat Commun. 2021 Sep 17;12(1):5492. doi: 10.1038/s41467-021-25617-0. PMID:34535643[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||